ORGAN TOXICITY IN ONCOLOGY DRUGS- IMMUNE CHECKPOINT INHIBITORS

Meredith K. Chuk, M.D.
Acting Associate Director for Safety
Office of Hematology and Oncology Products/CDER/FDA
Immune Checkpoint Inhibitors

• Immune checkpoint blockade enhances antitumor immune response

• Rapidly expanding area of drug development
  – several approved immune checkpoint inhibitors (anti-CTLA-4, anti-PD-1, anti-PDL-1) for a variety of oncology diseases

• Immune-mediated adverse reactions occur with all drugs in this class
Immune-Mediated Adverse Reactions (imARs)

- Unique spectrum of adverse reactions
- Can affect any organ system
  - Pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, dermatologic toxicities
- Vary in timing and severity
- Similar in presentation and management across drugs

(NEJM 2018; 378:158-68)
Management Considerations

• Benefit-risk assessment

• Management requires multi-specialty teams

• Treatment often includes:
  – Immune suppression (e.g. glucocorticoids) for non-endocrine imARs
  – Hormone replacement for endocrine imARs

• Areas of interest:
  – Retreatment after imAR, immune-suppression regimens, predictive factors, treatment of patients with baseline immune-mediated diseases